SPOP and prostate carcinoma: Somatic heterozygous missense mutations occurring at the level of the substrate-binding cleft of speckle-type PO2 protein (SPOP) gene were identified in up to 15% of human prostate cancers, thus making SPOP the gene most commonly affected by nonsynonymous point mutation in this cancer [125].